RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Viracta Therapeutics Stock

Viracta Therapeutics P/E 2024

Viracta Therapeutics P/E

-0.79

Ticker

VIRX

ISIN

US92765F1084

WKN

A2QQRS

As of Oct 3, 2024, Viracta Therapeutics's P/E ratio was -0.79, a -26.17% change from the -1.07 P/E ratio recorded in the previous year.

The Viracta Therapeutics P/E history

Viracta Therapeutics Aktienanalyse

What does Viracta Therapeutics do?

Viracta Therapeutics is a biopharmaceutical company specializing in the discovery and development of novel therapies for the treatment of virus-associated cancers. They have a unique business model based on modifying existing drugs to specifically target the virus affecting cancer cells. They have two product segments: one for treating patients with virus-associated cancers such as Epstein-Barr virus and human papillomavirus, and another for complementing existing cancer therapies. Viracta is a leading company in precision oncology and aims to fill gaps in cancer treatment. They are currently developing nanatinostat, pidilizumab, and voruciclib as potential treatments for various virus-associated cancers. Their goal is to make these medications available quickly and expand in the coming years through research, development, and collaborations with other companies. Viracta Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Viracta Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Viracta Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Viracta Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Viracta Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Viracta Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Viracta Therapeutics stock

What is the price-to-earnings ratio of Viracta Therapeutics?

The price-earnings ratio of Viracta Therapeutics is currently -0.79.

How has the price-earnings ratio of Viracta Therapeutics changed compared to last year?

The price-to-earnings ratio of Viracta Therapeutics has increased by -26.17% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Viracta Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Viracta Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Viracta Therapeutics affect the company?

An increase in the price-earnings ratio of Viracta Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Viracta Therapeutics affect the company?

A decrease in the price-earnings ratio of Viracta Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Viracta Therapeutics?

Some factors that influence the price-earnings ratio of Viracta Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Viracta Therapeutics pay?

Over the past 12 months, Viracta Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Viracta Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Viracta Therapeutics?

The current dividend yield of Viracta Therapeutics is .

When does Viracta Therapeutics pay dividends?

Viracta Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Viracta Therapeutics?

Viracta Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Viracta Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Viracta Therapeutics located?

Viracta Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Viracta Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Viracta Therapeutics from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Viracta Therapeutics pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Viracta Therapeutics in the year 2023?

In the year 2023, Viracta Therapeutics distributed 0 USD as dividends.

In which currency does Viracta Therapeutics pay out the dividend?

The dividends of Viracta Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Viracta Therapeutics

Our stock analysis for Viracta Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Viracta Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.